The B6 vitamins comprise three phosphorylated pyridine derivatives represented by pyridoxal 5′-phosphate (PLP), pyridoxamine 5′-phosphate and pyridoxine 5′-phosphate(Reference Coburn1). These derivatives are obtained from a diverse array of food items, including meat, milk products, beans, nuts, potatoes and several fruits and vegetables(Reference Brown and Beier2). Following ingestion, these molecules undergo dephosphorylation by intestinal phosphatases, absorbed and then converted in the liver to the active form of vitamin B6, PLP. PLP serves as a cofactor for more than 140 enzymes and is therefore a critical component of many biochemical pathways(Reference Wilson, Plecko and Mills3). It has roles in the immune system(Reference Cheng, Chang and Lee4), neurotransmission and brain function(Reference Brown and Beier2), synthesis of metabolic products like lipids and amino acids(Reference Clayton5), as a modulator of transcription factors(Reference Lambrecht, Braun and Damer6) and in redox systems(Reference Bilski, Li, Ehrenshaft and Daub7). PLP is considered as one of the most sensitive markers for vitamin B6 status in humans(Reference Lotto, Choi and Friso8). In recent times, lifestyle factors such as smoking(Reference Ulvik, Ebbing and Hustad9), alcohol consumption(Reference Lumeng and Li10) drug consumption(Reference Porter, Ward and Hughes11) and differing dietary patterns such as vegetarianism(Reference Schüpbach, Wegmüller and Berguerand12) have been reported to be key drivers of low dietary vitamin B6 intake or PLP concentration reduction. Indeed, it is now widely recognised that diminished dietary vitamin B6 intakes correlate with CVD(Reference Tavani, Pelucchi and Parpinel13), Parkinson’s disease(Reference Murakami, Miyake and Sasaki14) and some cancers(Reference Theodoratou, Farrington and Tenesa15). Moreover, increased evidence points to stronger associations of PLP level reduction with increased risk of CVD including stroke(Reference Kelly, Shih and Kistler16), irritable bowel syndrome(Reference Moon, Figgins and Altshuler17), thrombosis(Reference Saibeni, Cattaneo and Vecchi18), severity of COVID-19 infection(Reference Shakoor, Feehan and Mikkelsen19) and diabetes(Reference Nix, Zirwes and Bangert20). Importantly, PLP level reduction can be caused by certain medical procedures and genetic factors, for example, in renal transplant recipients(Reference Minović, van der Veen and van Faassen21), adult intestinal transplant recipients(Reference Matarese, Dvorchik and Costa22) and in those suffering seizures(Reference Ghatge, Al Mughram and Omar23). These links correspond with the known functional roles of PLP in many enzymes catalysed reactions important in the immune system(Reference Cheng, Chang and Lee4), trans-methylation(Reference Parra, Stahl and Hellmann24) and trans-sulphuration pathways(Reference Sbodio, Snyder and Paul25). Nutrient deficiencies are of a global health concern(Reference Tulchinsky26) due to their associations with many chronic health conditions(Reference Oz27). Reduction in dietary vitamin B6 intake is bolstered by ageing(Reference Planells, Sanchez and Montellano28), rates of undernutrition(Reference Yisak, Maru and Abie29) and smoking(Reference Dyer, Elliott and Stamler30). Moreover, the usage of medications may also be an important driver of deficiency(Reference Porter, Ward and Hughes11). Worldwide the number of drug prescriptions has increased, particularly in developed countries(Reference Hovstadius, Hovstadius and Åstrand31). Indeed, in the UK alone, the number of drug prescriptions increased by 65% between 1999 and 2009(Reference Zhang, Mamtani and Scott32). Moreover, in England, among elderly populations (65+), the number of individuals taking five or more types of medications has increased from 12 % to 49 % in the last two decades(Reference Gao, Maidment and Matthews33). In view of the widespread use of prescription drugs, the current work seeks to assess lifestyle factors and medication usage on dietary vitamin B6 intake and plasma PLP concentration in the general UK adult population (≥ 19 years) using the National Diet and Nutrition Survey Rolling Programme (NDNS-RP; 2008–2017). Only a limited number of studies have explored how lifestyle factors impact on vitamin B6 intake and PLP levels in humans. Therefore, the current research utilised the NDNS dataset to establish dietary vitamin B6 and plasma PLP concentrations and assessed how a wide range of lifestyle factors and medications influence the levels of these important nutrients in humans.
Materials and methods
The National Diet and Nutrition Survey Rolling Programme
NDNS-RP is a national cross-sectional survey to assess diet, nutrient intake and nutritional status of the UK population aged 1·5 years and above, who live in a private household. Data from the NDNS were obtained from the UK Data Service (https://www.ukdataservice.ac.uk/). Detailed methodology is reported in the user guide for UK data and elsewhere(Reference Venables, Roberts and Nicholson34); however, briefly, to produce representative data of the UK population, this survey was carried out in all four UK countries: England, Scotland, Wales and Northern Ireland. The survey was designed to recruit 1000 subjects annually (500 children (1·5 years to 18 years) and 500 adults (19 years and above)), with a boost sample of an additional 600 subjects. Sample selection was conducted randomly from the Postcode Address File, a list of all UK addresses. These addresses were then clustered into primary sampling units, smaller geographical areas based on postcode sectors, to enhance cost-effectiveness. From each primary sampling unit, a list of addresses was selected randomly. To reach this sample, trained interviewers contacted the addresses to enrol the participants, based on two stages, namely interviewer (first) and nurse (second) stages. In the current study, the most recent timepoint in NDNS when we started the work was 2017. As such, the individual and personal level dietary data from all years (2008–2017) were joined by one researcher S.W. in SPSS file form. Both male and female aged 19 years and above were included in the current work.
First stage: dietary data, smoking and alcohol consumption
During the initial visit by trained fieldworkers, a face-to-face computer-assisted personal interview was performed with each participant. Dietary data were obtained by using four days’ estimated food diaries that were explained to the participants. In year 1 of the study, dietary recording was always started on Thursday, Friday or Saturday and included both weekend days, while in year 2, the study was designed to over-represent weekdays than weekends. From year 3 onwards, dietary recording was started on any day of the week for four consecutive days (to evenly represent all weekdays). Briefly, participants were asked to report foods and drinks that were consumed, both in and outside the home, during the 4 days: including brand name, portion size and recipe if home-cooked. Household measures (e.g. 4 teaspoons of peanut butter) or weights reported on labels (e.g. 200 ml can of lemonade) were used to estimate portion sizes. Then, each food or drink item was assigned a code and dietary assessment was performed using a platform called Diet In Nutrients Out (DINO) – developed at the Medical Research Council (MRC) Elsie Widdowson laboratory (MRC EWL) – that is based on Public Health England’s NDNS Nutrient Databank food composition data. In fact, this database is updated annually by the Food Standards Agency to revise the existing food codes or remove foods that are no longer sold in the UK. According to the British Nutrition Foundation, the reference nutrient intake (RNI) for dietary vitamin B6 intake for adults aged 19 years and above is 1·4 mg/d for male and 1·2 mg/d for female. In the current study, participants who used supplementation were excluded.
During the interviewer stage, types of diet was collected from participants by an interview and defined as omnivore or vegetarian or vegan. Additionally, smoking status was also assessed and collected by self-completion questionnaires; in this study, the number of cigarettes per day was defined as follows: non-smokers or 1–5 cigarettes/d or 6–9 cigarettes/d or ≥ 10 cigarettes/d. Moreover, drinking habit – collected by self-completion questionnaires – was categorised as follows: ((non-alcoholic or ≤ 4 units/d (men) and ≤ 3 units/d (women)) or (> 4 units/d and ≤ 8 units/d (men), > 3 units/d and ≤ 6 units/d (women)) or (> 8 units/d units (men) and > 6 units/d units (women))).
Height and weight were measured using a portable stadiometer, and BMI (kg/m2) was calculated as weight (kg) divided by height (m) squared. Only participants with three or four completed days of the food diary were invited to the second stage of the survey to participate in blood measurements.
Second stage: laboratory measurements and medication use
Participants who took part in computer-assisted personal interview and completed at least three dietary records were asked to be involved in the second stage of the surveys, which took the form of a nurse visit – to take blood samples in participants’ homes by trained nurses. The nurse stage was carried out within 2–4 months of the final reviewer visit. Following overnight fasting, blood samples were obtained by venepuncture-trained nurses or phlebotomists and stored in a cool box (at approximately 4°C). Samples were delivered to a locally recruited laboratory for prompt analysis within 2 hours of collection. Then, samples were processed and stored at −40°C before transporting on dry ice and delivering to MRC EWL, where samples were stored frozen at −80°C until analysis was conducted.
Since all dietary vitamin B6 forms are converted to PLP, PLP levels were assessed in this study. PLP concentration in plasma was measured with a reverse-phase HPLC method with post-column derivatisation and fluorometric detection as described(Reference Rybak and Pfeiffer35). In this work, the cut-off of vitamin B6 deficiency is < 20 nmol/l of plasma PLP concentration, while 20–<30 nmol/l is indicative of marginal deficiency(Reference Spinneker, Sola and Lemmen36,Reference Leklem37) . Furthermore, during this visit, prescribed medication use information was collected. However, no details were reported regarding the duration and doses of the used medications
Ethics
The NDNS was conducted according to the guidelines laid down in the Declaration of Helsinki. The ethical approval of all procedures including human subjects was obtained from the Oxfordshire A Research Ethics Committee for the NDNSD-RP 2008–2013 (Ref. No. 07/H0604/113), while for the NDNS-PR 2014–2017, the approval was obtained from the Cambridge South NRES Committee (Ref. No. 13/EE/0016). The study is registered with the ISRTCN registry as ISRCTN17261407 (https://www.isrctn.com/ISRCTN17261407). Written informed consent was obtained from all participants.
Data analysis
Analyses were performed in IBM SPSS® Statistics for Windows, Version 27. Since the data were not normally distributed, data presented as median values and 25th–75th percentiles (Max and Min values were also reported) or numbers and percentages. Total sample dietary vitamin B6 intakes and plasma PLP concentrations were analysed by sex and age group – stratified by decades. Mann–Whitney U-test was used to compare differences between two categorical data. For more than two covariates comparison, Kruskal–Wallis H with post-hoc Tukey test was used. In GenStat 22nd edition, linear regression analysis was used to investigate associations between dietary vitamin B6 intakes and plasma PLP concentrations, taking into consideration age group and sex. Plasma PLP concentration was log10 transformed for normalisation and subject to multiple linear regression analyses to test associations between plasma PLP concentration/dietary vitamin B6, drugs and lifestyle factors. P values ≤ 0·05 were considered statistically significant throughout the study.
Results
Study population characteristics
From the NDNS cohort, 6802 participants aged ≥ 19 years were included in this study. The demographic characteristics of participants are presented in Table 1. Median (25th–75th percentile) age of the total population was 49 (36–63), with a higher percentage of female respondents than male noted in the current work (59 % and 41%, respectively). Median (25th–75th percentile) BMI of the total population was 27 (24–31) kg/m2, with 29% of total population categorised as obese (BMI ≥ 30 kg/m2) and 38% overweight (BMI = 25–29·9 kg/m2) (Table 1). However, not all participants reported BMI. Participant’s characteristics regarding lifestyle factors, including smoking, alcohol consumption, type of diet and medication usage, are summarised in Table 1. For data focussed on medication, twelve therapeutic drugs were reported in the NDNS data set (Table 1).
Characteristics of UK adults aged 19 and above from NDNS, 2008–2017
NDNS, National Diet and Nutrition Survey Rolling Programme; PPI, proton pump inhibitor.
General patterns of dietary vitamin B6 and plasma pyridoxal 5′-phosphate concentration in the UK population
The median (25th–75th percentile) intakes of dietary vitamin B6 across the whole population (1·7 (1·4–2·3) mg/d) met the RNI for both females and males (1·2 and 1·4 mg/d respectively, Fig. 1). Moreover, males consumed more dietary vitamin B6 than females (2·1 (1·6–2·8) mg/d and 1·6 (1·2–2) mg/d respectively; P < 0·001). We found a significant association between dietary intake of vitamin B6, sex and age group in the total population (P < 0·001), using multiple linear regression analysis (online Supplementary 10), which confirmed the general trend of age-dependent reductions in dietary vitamin B6 in each sex (P < 0·001) (Table 2). Among males, significant reductions were seen in the oldest group (≥80+ group) compared with all other groups. A similar trend for females aged ≥ 80+ years was also noted with his trend becoming apparent when comparing against the 30–39 years, 50–59 years and 60–69 years groups (P < 0·05) (Table 2).
Dietary vitamin B6 intake among UK adults aged ≥ 19 years based on sex and age group, 2008–2017.
Vitamin B6 intake and plasma PLP concentration among UK adults aged ≥19 years based on sex and age group, 2008–2017
PLP, pyridoxal 5' phosphate; plasma PLP concentration of < 20 nmol/l is indicative of vitamin B6 deficiency, while 20–<30 nmol/l is indicative of marginal deficiency. RNI for dietary vitamin B6 intake for adults aged 19 years and above is 1·4 mg/d for male and 1·2 mg/d for female. Mann–Whitney U-test was used to assess the significant differences between two categorical data, while the Kruskal–Wallis H test was used for more than two groups as described in the method. Data are expressed as median (25th–75th percentiles).
The median (25th–75th percentile) concentrations of plasma PLP across the whole population (42·8 (28·6–63·9) nmol/l) were above the cut-off of vitamin B6 deficiency (above the cut-off of < 20 nmol/l) (Table 2). Moreover, 90 % of total population had plasma PLP concentrations above the cut-off of < 20 nmol/l. However, 10 % showed vitamin B6 deficiency (plasma PLP concentration < 20 nmol/l), while 17 % of the total population had marginal vitamin B6 deficiency (plasma PLP concentration 20–< 30 nmol/l) (online Supplementary 1). Like dietary vitamin B6, females had lower median plasma PLP concentration compared with males (39·9 (27·1–58·8) nmol/l and 47·4 (31·1–69·8) nmol/l, respectively; P < 0·001); however, both sexes were above the cut-off of vitamin B6 deficiency. In fact, 12 % of female participants had vitamin B16 deficiency compared with 9 % of male participants (online Supplementary 1). Moreover, as shown in the regression analysis (online Supplementary 10), there was a significant association between plasma PLP concentration and age group in the total population (P < 0·001), but not with sex (P = 0·2).
Also noted is a significant reduction in PLP levels with advancing age among both sexes, reaching a low of 28·7 (16·8–41·2) nmol l–1(P < 0·001) in males and 31·5 (20·1–53·3) nmol l–1 (P < 0·001) for females aged ≥ 80 years (Table 2). However, these values were still above the cut-off of deficiency (Fig. 2). Among males, a significant negative association was found between the 80+ years group and 60–69 years, 50–59 years, 40–49 years, 30–39 years, 19–29 years, P < 0·001. Similarly, among female aged ≥ 80+ years association was found when compared with the 50–59 years group (Table 2). A significant association between dietary vitamin B6 intake and log10 plasma PLP concentration is reported in the current analysis (R2 = 0·07, P < 0·001) (Fig. 3).
Plasma PLP concentration among UK adults aged ≥ 19 years based on sex and age group, 2008–2017. PLP, pyridoxal 5′-phosphate.
Associations between dietary vitamin B6 intake and plasma PLP concentration among UK adults aged ≥ 19 years based on sex and age group, 2008–2017. PLP, pyridoxal 5′-phosphate.
Dietary vitamin B6, plasma pyridoxal 5′-phosphate level and lifestyle
Type of diet
Differences in plasma PLP levels had a general trend of matching specific type of diets; however, these changes were not statistically significant (Table 3). Participants who were vegetarian tended to have the lowest levels of plasma PLP concentration and dietary vitamin B6 intake compared with omnivore and vegan groups (36·8 (22·5–58·1) nmol l–1, 42·9 (28·7–64) nmol l–1 and 48·3 (42·8–69·3) nmol l–1 respectively; P = 0·1) and (1·4 (1·1–2) mg d–1, 1·7 (1·4–2·3) mg d–1 and 1·8 (1·4–2·2) mg d–1 respectively; P < 0·001). Of the included vegetarians, 13 % had vitamin B6 deficiency and 22 % had marginal deficiency compared with 10 % and 17 % of omnivores, respectively (online Supplementary 2). In the current research, no association was found after doing the regression analysis (online Supplementary 10) between diet types and dietary vitamin B intake nor plasma PLP concentrations.
The impact of type of diet, smoking and alcohol consumption on vitamin B6 intake and plasma PLP concentration among UK adults aged ≥ 19 years
PLP, pyridoxal 5′ phosphate. Mann–Whitney U-test was used to assess the significant differences between two categorical data, while the Kruskal–Wallis H test was used for more than two groups as described in the method. Data are expressed as median (25th–75th percentiles).
Smoking and alcohol consumption
Results showed an association between smoking and reduction in plasma PLP concentration (P < 0·001) but not with dietary vitamin B6. Plasma PLP concentrations differed within the smoker group and were linked with the numbers of cigarettes smoked per day (Table 3). Results showed that people who smoked ≥ 10 cigarettes a day had a significantly lower plasma PLP concentration as compared with the non-smokers and those smoking fewer cigarettes per day (32·3 (21·5–50) nmol l–1 and 46 (31–67) nmol l–1 and 41·9 (23·3–71·3) nmol l–1 and 33·1 (21·6–56·1) nmol l–1, P < 0·001: ≥ 10 cigarettes d–1 and non-smoker and 1–5 cigarettes d–1 and 6–9 cigarettes d–1, respectively). We found 21 % of people who smoked ≥ 10 cigarettes d–1 had vitamin B6 deficiency compared with 6 % of non-smokers (online Supplementary 2).
A general trend showed that higher plasma PLP concentrations among people who consume higher units/d compared with non-alcoholic and lower units/d of alcohol (P < 0·01; Table 3). However, no association was found between alcohol and dietary vitamin B6 intake (online Supplementary 10).
Medication use
Dietary vitamin B6 intake and plasma PLP concentrations differed among users of medication as compared with non-users (Table 4). Among the reported medications (Table 1), dietary vitamin B6 levels were unaffected by most medication usage, except for those using analgesic, antidepressants, Ca blockers and diuretic and proton pump inhibitors. Users of these classes of the drug showed significant reductions in vitamin B6 among the users compared with the non-users (Table 4). However, regression analysis (online Supplementary 10) showed that dietary vitamin B6 intake was associated only with an antidepressant (P = 0·007).
The impact of therapeutic drug use on vitamin B6 intake and plasma PLP concentration among UK adults aged ≥ 19 years
PLP, pyridoxal 5' phosphate. Mann–Whitney U-test was used to assess the significant differences between two categorical data, while the Kruskal–Wallis H test was used for more than two groups as described in the method. Data are expressed as median (25th–75th percentiles).
Moreover, almost all the medication users, except antibacterial and ACE inhibitor groups, showed significant reductions in plasma PLP levels compared with the non-users (P ≤ 0·01: Table 4). Among the reported twelve medications, we found that seven drugs were associated with reduced plasma PLP concentrations which are analgesics, antibacterial, antidiabetics, antidepressant, Ca blockers, prescribed asthma and lipid-lowering drugs (P < 0·001, P = 0·04, P = 0·002, P = 0·03, P = 0·03, P = 0·003 and P = 0·01, respectively; online Supplementary 10), which confirmed the general trend of plasma PLP reduction among the medication users. Importantly, the percentage of participants who had vitamin B6 deficiency was higher in all the medication users compared with non-users (online Supplementary 3).
Discussion
Evidence from epidemiological and animal studies reports that diminished vitamin B6 intake and plasma PLP concentrations are associated with negative health outcomes in humans(Reference Shen, Lai and Mattei38–Reference Vanuzzo, Pilotto and Lombardi43). The current study sought to utilise the available NDNS datasets to determine dietary vitamin B6 intake and plasma PLP concentration in free-living adults, representative of the general UK population (≥ 19 years). In general, most participants met the RNI for vitamin B6 intake and were above the cut-off of vitamin B6 deficiency (plasma PLP concentrations were above 20 nmol/l). However, 10 % of the total population had vitamin B6 deficiency, while 17 % had marginal vitamin B6 deficiency. A noted tendency for both dietary vitamin B6 intake and plasma PLP concentration was that these tended to decrease with age and also with lifestyle factors such as smoking and medication usage.
When the data were stratified for age, a significant difference in vitamin B6 intake and plasma PLP concentrations in each sex was seen (Table 2). The age-related declines in both dietary vitamin B6 intake and plasma PLP concentration (Table 2) previous parallel observations in the elderly(Reference Kjeldby, Fosnes and Ligaarden44,Reference Rose, György and Butler45) and changes documented in the current research indicate reductions in both vitamin B6 intake and plasma PLP concentration across age groups (P < 0·001) (Table 2). Moreover, we reported significant associations between plasma PLP concentration, dietary vitamin B6 and age group (P < 0·001).
The significance of these findings is highlighted by the knowledge that low dietary vitamin B6 intakes in the elderly are associated with frailty(Reference Balboa-Castillo, Struijk and Lopez-Garcia46), impaired mobility risk reduction (OR = 0·66;(Reference Struijk, Lana and Guallar-Castillón47)), physical performance(Reference Grootswagers, Mensink and Berendsen48), increased serum homocysteine levels(Reference Chen, Pan and Yang49), cognitive impairment(Reference Hughes, Ward and Tracey50) and immune function impairment(Reference Meydani, Ribaya-Mercado and Russell51). Moreover, a recent meta-analysis revealed an inverse correlation between dietary vitamin B6 and CVD (P < 0·05;(Reference Jayedi and Zargar52)). Therefore, long-term, suboptimal levels of vitamin B6 intake could predispose individuals to various health risks. Similarly, low plasma PLP levels predispose to a higher risk of venous thrombosis(Reference Cattaneo, Lombardi and Lecchi53), myocardial infarction(Reference Page, Ma and Chiuve54), diabetes mellitus(Reference Rubí55), COVID-19 infection(Reference Tomasa-Irriguible, Bielsa-Berrocal and Bordejé-Laguna56), oxidative stress(Reference Shen, Lai and Mattei38), increasing risk of cancer in diabetic patients(Reference Merigliano, Mascolo and Burla57,Reference Kelly, Kistler and Shih58) , immune system disruption and CRP level elevations(Reference Friso, Jacques and Wilson39) that suggests increased risk of inflammation conditions(Reference Kelly, Kistler and Shih58). These associations indicate the importance of both dietary vitamin B6 intake and plasma PLP concentration in age-related health conditions (reviewed in Parra and colleagues(Reference Parra, Stahl and Hellmann24)). While it is acknowledged that the participants in the current research are free living UK population, the observed declines in dietary vitamin B6 intake and plasma PLP concentration maybe more significant in those members of the general population suffering from chronic ill health, reduced food intakes or those residing in care homes(Reference Joosten, van den Berg and Riezler59). Clearly, given the important roles of these molecules in ageing, stress response, drug metabolism and the immune system(Reference Stach, Stach and Augoff60), further research is warranted. To date, a small number of human intervention studies have assessed vitamin B6 supplementation on health, and these show that increased vitamin B6 intakes is beneficial to health(Reference Cheng, Chang and Lee4,Reference Cheng, Lin and Liu61,Reference Huang, Wei and Wu62) .
Few human clinical trials have been reported that assess vitamin B6 or associated metabolites ( https://clinicaltrials.gov/ct2/results?term=Pyridoxal+5%27Phosphate&Search=Search), of these, most are combinational treatments of PLP alongside various therapeutics making interpretation difficult. Few studies have assessed PLP supplementation alone in the elderly to manage age-related health conditions. While all participants in the current work still meet their RNI for vitamin B6 intake and are above the cut-off of < 20 nmol/l of plasma PLP concentration, levels are diminished with age and this could pose potential health risks, and further studies are needed.
Lifestyle factors such as smoking, alcohol consumption and therapeutic drug usage were common among participants in the current work. We found an association between smoking and reduction in plasma PLP concentrations (P < 0·001) but not with dietary vitamin B6. In the smoking groups, levels of plasma PLP decreased with increased cigarette usage (10+ per day), with 21 % of people who smoke ≥ 10 cigarettes d–1 having plasma PLP levels below the cut-off of vitamin B6 deficiency. A similar result to that reported by Jain and Lim(Reference Jain and Lim63). While data are sparse, the possible reasons for this are proposed increases in the activity of PLP-dependent enzymes such as alanine phosphatase and reduction in the levels of serum albumin, both common in smokers(Reference Vermaak, Ubbink and Barnard64).
Furthermore, positive association between plasma PLP concentration and alcohol is reported. We found the non-alcohol-consuming participants had the lowest dietary vitamin B6 compared with people who drink alcohol, although no association was found between alcohol and dietary vitamin B6 intake in this study. Van Der Gaag and colleagues(Reference van der Gaag, Ubbink and Sillanaukee65) found serum PLP levels were reportedly increased by 17 %, 15 % and 30 % following the consumption of three servings of wine, spirits and beer over 3 weeks alcohol consumption period. This could be due to the fact that beer contains vitamin B6(Reference van der Gaag, Ubbink and Sillanaukee65). In our study, beer drinkers had higher dietary vitamin B6 intake and plasma PLP concentration than non-drinkers (online Supplementary 5 showed vitamin B6 intake and plasma PLP concentration among different types of alcoholic beverages in the NDNS dataset).
Moreover, in people following different types of diets, like vegetarians and vegans, no significant differences in plasma PLP levels were noted in these groups. This may be reflective of diet diversity or supplementation(Reference Schorgg, Bärnighausen and Rohrmann66) (online Supplementary 4).
The most significant observation made in the current research was the impact of medication on vitamin B6 intakes and plasma PLP levels. Interestingly, it is noteworthy that the number of prescription drugs taken in this population increased with advancing age (online Supplementary 6). This finding correlates with previous studies showing on average that therapeutic drug use is stratified as follows 50–60 years (2 drugs)(Reference Zhang, Mamtani and Scott32), 60–70 years (3–4 drugs)(Reference Bamforth67) and 70+ years (4–10 drugs)(Reference Christensen, Reilev and Juul-Larsen68). Twelve drug groups were identified based on therapeutic drug use, ranging from analgesics to proton pump inhibitor (as shown in Table 1). It was noteworthy that there were associations between reductions in plasma PLP concentrations and usage of analgesics, antibacterial, antidiabetics, antidepressant, calcium blockers, asthma prescriptions and lipid-lowering drugs. Low dietary vitamin B6 intake was only associated with an antidepressant. Other medications have previously been reported to diminish vitamin B6 status, such as antiepileptic(Reference Clayton5) and oral contraceptives(Reference Wilson, Bivins and Russell69). While reduced levels of plasma PLP concentrations among the medication users are above the threshold of vitamin B6 deficiency (above 20 nmol/l of plasma PLP concentration) (Table 4), these drug groups could be impacting on susceptible individuals such as the elderly. Indeed, long-term use of medications is common among aged populations to manage long-term conditions and one could speculate that polypharmacy in these groups could be driving nutrient deficiencies and in turn health complications(Reference Gao, Maidment and Matthews33). Among the elderly, aged 65–79 years, vitamin B6 intakes are positively associated with handgrip strength(Reference Grootswagers, Mensink and Berendsen48) and physical performance(Reference Behrouzi, Grootswagers and Keizer70). In fact, Kjeldby and colleagues(Reference Kjeldby, Fosnes and Ligaarden44) found that PLP levels were normal among all elderly people (mean age of 85·3 years) who used vitamin B6 supplements as compared with non-users having a deficiency. Among the elderly, vitamin B6 supplements were seen to improve immune responses post 2 months of a 50 mg/d of vitamin B6 supplementation(Reference Talbott, Miller and Kerkvliet71). Similarly, vitamin B6 supplementation (20 mg/d for three months) was seen to improve memory health in the elderly(Reference Deijen, Van der Beek and Orlebeke72).
Collectively, the current work highlights the provision of the NDNS dataset for the assessment of health and nutrient-related interactions. The current research found important links between lifestyle factors and vitamin B6 intake and plasma PLP levels, which are important for health. Mitigation of vitamin B6 deficiency and targeting people at risk of nutritional deficiency could help in reducing health-related comorbidities. UK adults (≥ 19 years) met RNI of vitamin B6 intake and were above the cut-off of vitamin B6 deficiency; however, a common pattern that emerged from this study was the tendency for both vitamin B6 intake and PLP concentrations to decrease with age and lifestyle factors such as smoking and medication usage. Importantly, medication usage frequently showed a negative impact on plasma PLP levels in humans. This information could be an important consideration in the nutritional assessment of the elderly, particularly those that smoke or individuals using polypharmacy. However, it must be acknowledged that the limitations of the current findings are the lack of information relating to dosage and duration of drug use in the participants and the timing between food diaries and blood samples in the NDNS. Another limitation of the current work is that the available data on vitamin B status does not take into account the metabolic turnover of vitamin B6 in the respective population. Past research indicates that plasma PLP concentration measures are robust markers of vitamin B6 status; however, they may not reflect the total subcellular compartmentalisation of vitamin B6. Clearly, further work is needed in this field of research.
Acknowledgements
The Saudi Arabian Government and the Jazan University, Saudi Arabia.
This research was supported by the Saudi Arabian Government and the Jazan University, Saudi Arabia. The Jazan University had no role in the design, analysis or writing of this article. The NDNS is funded by the Food Standards Agency and the Department of Health.
Conceptualisation: A. A., S. W. and P. R.; methodology: A. A., S. W. and P. R.; formal analysis: A. A., and P. R.; investigation: A. A., S. W. and P. R.; writing—original draft preparation: A. A.; writing—review and editing: A. A., S. W. and P. R.; visualisation: A. A.; supervision: S. W. and P. R.; funding acquisition: A. A., S. W. and P. R. All authors have read and agreed to the published version of the manuscript.
There are no conflicts of interest.
Supplementary material
For supplementary material/s referred to in this article, please visit https://doi.org/10.1017/S0007114523000417
Open access
